Skip to main content
Have a personal or library account? Click to login
Doses in organs at risk during head and neck radiotherapy using IMRT and 3D-CRT Cover

Doses in organs at risk during head and neck radiotherapy using IMRT and 3D-CRT

Open Access
|Nov 2012
Read online

References

  1. 1. Gabrys D, Wesolowska I, Suwinski R. The evaluation of 3DRT and IMRT techniques in postoperative radiotherapy for thyroid medullary carcinoma. Rep Pract Oncol Radiother 2008; 13: 126-9.10.1016/S1507-1367(10)60002-8
  2. 2. Miften MM, Das SK, Su M, Marks LB. A dose-volume-based tool for evaluating and ranking IMRT treatment plans. J Appl Clin Med Phys 2004; 5: 1-14.10.1120/jacmp.v5i4.1981
  3. 3. Trojanowska A. Squamous cell carcinoma of the head and neck-The role of diffusion and perfusion imaging in tumor recurrence and follow-up. Rep Pract Oncol Radiother 2011; 16: 203-8.10.1016/j.rpor.2011.06.006
  4. 4. Buettner F, Miah AB, Gulliford SL, Hall E, Harrington KJ, Webb S, et al. Novel approaches to improve the therapeutic index of head and neck radiotherapy: An analysis of data from the PARSPORT randomised phase III trial. Radiother Oncol 2012; 103: 82-7.10.1016/j.radonc.2012.02.006
  5. 5. Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, et al. PARSPORT trial management group. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 2011; 12: 127-36.10.1016/S1470-2045(10)70290-4
  6. 6. Binhu J, Supe S, Pawar Y. Intensity modulated radiotherapy (IMRT) the white, black and grey: a clinical perspective. Rep Pract Oncol Radiother 2009; 14: 95-103.10.1016/S1507-1367(10)60101-0
  7. 7. Rosenthal DI, Chambers MS, Fuller CD, Rebueno NCS, Garcia J, Kies MS, et al. Beam path toxicities to non-target structures during intensity-modulated radiation therapy for head and neck cancer. Int J Radiat Oncol Biol Phys 2008; 72: 747-55.10.1016/j.ijrobp.2008.01.01218455324
  8. 8. Sas-Korczyńska B, Śladowska A, Rozwadowska-Bogusz B, Dyczek S, Lesiak J, Kokoszka A, et al. Comparison between intensity modulated radiotherapy (IMRT) and 3D tangential beams technique used in patients with early-stage breast cancer who received breast-conserving therapy. Rep Pract Oncol Radiother 2010; 15: 79-86.10.1016/j.rpor.2010.06.002386316224376929
  9. 9. Lee N, Puri DR, Blanco AI, Chao KSC. Intensity modulated radiation therapy in head and neck cancers: An update. Head Neck 2007; 29: 387-400.10.1002/hed.2033216358297
  10. 10. Bhide SA, Nutting CM. Advances in radiotherapy for head and neck cancer. Oral Oncology 2010; 46: 439-41.10.1016/j.oraloncology.2010.03.00520409746
  11. 11. Clark CH, Hansen VN, Chantler H, Edwards C, James HV, Webster G, et al. Dosimetry audit for a multi-centre IMRT head and neck trial. Radiother Oncol 2009; 93: 102-8.10.1016/j.radonc.2009.04.025
  12. 12. Tribius S, Bergelt C. Intensity-modulated radiotherapy versus conventional and 3D conformal radiotherapy in patients with head and neck cancer: Is there a worthwhile quality of life gain? Cancer Treat Rev 2011; 37: 511-9.
  13. 13. Piotrowski T, Martenka P, De Patoul N, Jodda A, Coevoet M, Malicki J, et al. The new two-component conformity index formula (TCCI) and dose-volume comparisons of the pituitary gland and tonsil cancer IMRT plans using a linear accelerator and helical tomotherapy. Rep Pract Oncol Radiother 2009; 14: 133-45.10.1016/S1507-1367(10)60028-4
  14. 14. Grzadziel A, Grosu A, Kneschaurek P. Three-dimensional conformal versus intensity-modulated radiotherapy dose planning in stereotactic radiotherapy: Application of standard quality parameters for plan evaluation. Int J Rad Oncol Biol Phys 2006; 66: S87-94.10.1016/j.ijrobp.2006.01.056
  15. 15. Pesznyak C, Polgar I, Weisz C, Kiraly R, Zarand P. Verification of quality parameters for portal image in radiotherapy. Radiol Oncol 2011; 45: 66-74.10.2478/v10019-010-0052-6
  16. 16. Bailey DW, Kumaraswamy L, Podgorsak MB. A Fully electronic intensitymodulated radiation therapy quality assurance (IMRT QA) process implemented in a network comprised of independent treatment planning, record and verify, and delivery systems. Radiol Oncol 2010; 44: 124-30.10.2478/v10019-010-0017-9
  17. 17. Mendenhall W, Mancuso A. Radiotherapy for head and neck cancer - is the “next level” down? Int J Radiat Oncol Biol Phys 2009; 73: 645-6.
  18. 18. Kry SF, Salehpour M, Followill DS, Stovall M, Kuban DA, Rosen II. The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2005; 62: 1195-203.10.1016/j.ijrobp.2005.03.053
  19. 19. Howell RM, Scarboro SB, Kry SF, Yaldo DZ. Accuracy of out-ofi-field dose calculations by a commercial treatment planning system. Phys Med Biol 2010; 55: 6999-7008.10.1088/0031-9155/55/23/S03
  20. 20. Prescribing, Recording, and Reporting Photon Beam Therapy (Report 50), ICRU Report No. 50; 1993.
  21. 21. Prescribing, Recording and Reporting Photon Beam Therapy (Report 62), (Supplement to ICRU Report 50), ICRU Report 62; 1999.
  22. 22. Reference Data for the Validation of Doses from Cosmic-Radiation Exposure of Aircraft Crew (ICRU 84), ICRU Report 84. Journal of the ICRU 2012; 10(2).
  23. 23. Hall E, Wuu C. Radiation-induced second cancers: the impact of 3D-CRT and IMRT1. Int J Radiat Oncol Biol Phys 2003; 56: 83-8.10.1016/S0360-3016(03)00073-7
  24. 24. Dorr W, Stewart FA. Retreatment tolerance of normal Tissues. In: Basic Clinical Radiobiology. Joiner M and van der Kogel A, editors. 4th Edition. London: Hodder Arnold; 2009. p. 259-90.10.1201/b13224-20
  25. 25. Marks LB, Yorke ED, Jackson A, Ten Haken RT, Comstine LS, Eisbruch A, et al. Use of normal tissue complication probability models in the clinic. Int J Rad Oncol Biol Phys 2010; 76(3 Suppl): S10-9.10.1016/j.ijrobp.2009.07.1754404154220171502
  26. 26. Kupchak C, Battista J, Van Dyk J. Experience-driven dose-volume histogram maps of NTCP risk as an aid for radiation treatment plan selection and optimization. Med Phys 2008; 35: 333-43.10.1118/1.2815943
  27. 27. Mendenhall WM, Amdur RJ, Palta JR. Intensity-modulated radiotherapy in the standard management of head and neck cancer: promises and pitfalls. J Clin Oncol 2006; 24: 2618 -23.10.1200/JCO.2005.04.7225
  28. 28. Chen AM, Hall WH, Li B-Q, Guiou M, Wright C, Mathai M, et al. Intensitymodulated radiotherapy increases dose to the brachial plexus compared with conventional radiotherapy for head and neck cancer. Br J Radiol 2011; 84: 58-63.10.1259/bjr/62332495
  29. 29. Longobardi B, De Martin E, Fiorino C, Delloca I, Broggi S, Cattaneo GM, et al. Comparing 3DCRT and inversely optimized IMRT planning for head and neck cancer: Equivalence between step-and-shoot and sliding window techniques. Radiother Oncol 2005; 77: 148-56.10.1016/j.radonc.2005.09.011
  30. 30. Winiecki J, Zurawski Z, Drzewiecka B, Slosarek K. Anatomy-corresponding method of IMRT verification. Rep Pract Oncol Radiother 2011; 16: 1-9.10.1016/j.rpor.2010.11.001
  31. 31. Malicki J., Litoborski M, Kierzkowski J, Kosicka G. How the implementation of an in-vivo dosimetry protocol improved the dose delivery accuracy in head and neck radiotherapy. Neoplasma 2004; 51: 155-8.
  32. 32. Knöös T, Kristensen I, Nilsson P. Volumetric and dosimetric evaluation of radiation treatment plans: radiation conformity index. Int J Radiat Oncol Biol Phys 1998; 42:1169-76.10.1016/S0360-3016(98)00239-9
  33. 33. Clark CH, Miles EA, Urbano MTG, Bhide SA, Bidmead AM, Harrington KJ, et al. Pre-trial quality assurance processes for an intensity-modulated radiation therapy (IMRT) trial: PARSPORT, a UK multicentre Phase III trial comparing conventional radiotherapy and parotid-sparing IMRT for locally advanced head and neck cancer. Br J Radiol 2009; 82: 585-94.10.1259/bjr/3196650519332518
  34. 34. Guerrero Urbano MT, Clark CH, Kong C, Miles E, Dearnaley DP, Harrington KJ, et al. Target volume definition for head and neck intensity modulated radiotherapy: Pre-clinical evaluation of PARSPORT trial guidelines. Clin Oncol 2007; 19: 604-13.10.1016/j.clon.2007.07.00117706404
  35. 35. Gizynska M, Zawadzka A. IMRT versus 3D-CRT for thyroid cancer. Pol J Med Phys Eng 2008; 14: 151-62.10.2478/v10013-008-0013-1
  36. 36. Malicki J. The importance of accurate treatment planning, delivery, and dose verification. Rep Pract Oncol Radiother 2012; 17: 63-5.10.1016/j.rpor.2012.02.001386326124377001
DOI: https://doi.org/10.2478/v10019-012-0050-y | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Language: English
Page range: 328 - 336
Submitted on: Jun 17, 2012
Accepted on: Sep 17, 2012
Published online: Nov 9, 2012
Published in print: Oct 1, 2012
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2012 Magdalena Peszynska-Piorun, Julian Malicki, Wojciech Golusinski, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons License.